Market Report Source

Overview

Introduction
Although only 5% of asthma suffers have severe asthma, these patients account for a disproportionately high percentage of healthcare spending, as asthma-related hospitalizations and emergency room visits are two of the costliest outcomes, which highlights the significant unmet need in this market.

Scope
Evaluation of the market potential and dynamics of Xolair, currently the only marketed respiratory monoclonal antibody
Examination of the key mediators in asthma and the evidence supporting their role
Identification and evaluation of fifteen monoclonal antibodies currently in preclinical or clinical development to treat asthma
Assessment of drivers and resistors of using monoclonal antibodies in the severe asthma market

Highlights
Xolair is set to dominate the respiratory monoclonal antibody market through to 2010, and data from the TENOR study may help Genentech and Novartis to further increase market penetration if a role for IgE in non-atopic asthma is identified.

Th2 mediators are the target of most respiratory monoclonal antibody programs, of which IL-13 is generating the greatest interest, with one third of programs targeting this mediator.

Although there is a significant unmet need among severe asthma patients who are non-responsive to corticosteroids, the price point of respiratory monoclonal antibodies will limit penetration in cost-conscious Europe, transforming the US into the dominant revenue-creation market.

Reasons to Purchase
Evaluate the current state of the monoclonal antibodies market and the market capture potential for these products in severe asthma
Assess the key technological trends to capitalize on opportunities in the respiratory monoclonal antibody sector
Identify possible targets to focus monoclonal antibody design”

Table of Contents

TABLE OF CONTENTS

CHAPTER 1 EXECUTIVE SUMMARY

Introduction

Scope and coverage of the Brief

Key findings from this Brief

CHAPTER 2 DISEASE CLASSIFICATION AND EPIDEMIOLOGY

Asthma is a significant global health problem

Characterising asthma pathophysiology: the role of the Th2 pathway in asthma symptoms

The Th2 pathway plays a central role in asthma

A series of complex events underlie asthma symptoms

A broad range of mediators are involved in asthma pathophysiology

Asthma attacks are triggered by a wide variety of factors

Asthma is a collection of inflammatory respiratory conditions

Eosinophilic/mast cell asthma, and neutrophilic asthma

Atopic vs. non-atopic asthma and how it ties in with early-onset vs. late-onset asthma

Characterizing asthma by symptom frequency and severity

Characteristics of the severe asthma patient population

Corticosteroids and bronchodilators are currently the most common asthma treatments

CHAPTER 3 USING MONOCLONAL ANTIBODIES TO TREAT ASTHMA

The evolution of the whole mAbs sector into a $10 billion market

Business model evolution

Therapy area evolution

Market potential for respiratory mAbs: the pros and cons with using mAbs for asthma

CHAPTER 4 CURRENT RESPIRATORY MONOCLONAL ANTIBODY TREATMENTS FOR ASTHMA: XOLAIR

What is the rationale behind targeting IgE in asthma?

Xolair: a $1 billion market potential by 2015

Xolair’s path to approval: what do other mAbs need to demonstrate?

Xolair label extension: opportunity in non-atopic asthma

CHAPTER 5 PIPELINE INNOVATIONS AND POTENTIAL TARGETS

Targeting mediators that underlie asthma symptoms

The development of mAbs that target these mediators: the pipeline

Pipeline evaluation: IL-13 set to drive interest

Technology evolution: development of humanized and fully human mAbs set to drive market growth

Maximizing market potential by effective patient population capture: addressing clinical trial design issues

APPENDIX

Bibliography

Papers

Miscellaneous

About Datamonitor

About Datamonitor Healthcare

Datamonitor Healthcare’s research and analysis methodologies

Disclaimer